Biomarkers Market - Global Outlook & Forecast 2022-2027

Biomarkers Market - Global Outlook & Forecast 2022-2027

In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market Report

Biomarkers are increasingly useful tools to predict prognosis and response to therapy in cancer patients. Furthermore, it allows to improve understanding of mechanisms of action and resistance to treatment.

The global biomarkers market is expected to grow at a CAGR of 11.44%.

KEY HIGHLIGHTS

  • Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them.
  • Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinson’s and Alzheimer's disease and clinical outcome assessments.
  • Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. There are more emerging companies increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers.
  • Technological Advancements in Biomarker Discovery are also positively impacting the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.
GROWTH ENABLERS
  • Increase In Number of Pipeline Biomarkers
  • Rising Adoption of Biomarkers In Disease Diagnostics
  • Technological Advancements in Biomarker Discovery
GLOBAL BIOMARKERS MARKET SEGMENTATION

Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide. Biomarkers in the field of oncology has revolutionized the diagnostics and treatment pathways.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies is expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

Diagnostic biomarker dominated the type of segment as diagnostic biomarker studies have entered a new era where it holds promise for early diagnosis and effective treatment of many diseases.

Segmentation by Indication
  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Others
Segmentation by Application
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine (PM)
  • Others
Segmentation by Type
  • Diagnostic Biomarker
  • Monitoring Biomarker
  • Prognostic Biomarker
  • Susceptibility Biomarker
  • Other Biomarker
VENDOR ANALYSIS

Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.

Key Vendors
  • Abbott company
  • BioMerieux
  • Biohit OYJ
  • CENTOGENE
  • Creative Diagnostics
  • F. Hoffmann-La Roche company
  • Fujirebio
  • General Electric (GE) company
  • TAmiRNA
Other Prominent Vendors
  • Accure Therapeutics
  • Agilent
  • Almac Group
  • Applied Research Using OMIC Sciences (AROMICS)
  • Bio-Rad Laboratories
  • BioVision
  • Caris Life Sciences
  • Denovo Biopharma
  • Dreamgenics
  • Eisai
  • Epigenomics
  • Immunovia
  • Insilico Medicine
  • Lexogen
  • Monument Tx
  • Oryzon Genomics
  • Plexision
  • Rules-Based Medicine
  • Siemens Healthineers
  • Second Genome Therapeutics
  • Thermo Fisher Scientific
  • Ymir Genomics
GEOGRAPHICAL ANALYSIS

North America dominated the geography because biomarkers have been in use highly for diagnostic purposes, drug discovery & development, and precision medicine. The increase in R&D expenditures and fundings for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors in all the regions.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance the biomarker-based testing and increasing demand for biomarkers in drug development and personalized medicine are one of the primary factors in the region.

Segmentation by Geography
  • North America
US

Canada
  • Europe
Germany

France

UK

Italy

Spain
  • APAC
Japan

China

India

South Korea

Australia
  • Latin America
Brazil

Mexico

Argentina
  • Middle East & Africa
Turkey

South Africa

Saudi Arabia

THE REPORT INCLUDES:

1. The analysis of the global Biomarkers market size and growth rate for the forecast period 2022-2027.

2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global Biomarkers market.

3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.

4. It offers a complete overview of market segments and the regional outlook of the Biomarkers market.


1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.4 MARKET SEGMENTS
4.4.1 MARKET SEGMENTATION BY INDICATION
4.4.2 MARKET SEGMENTATION BY APPLICATION
4.4.3 MARKET SEGMENTATION BY TYPE
4.4.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
8 MARKET OPPORTUNITIES & TRENDS
8.1 INCREASED ADOPTION OF BIOMARKERS IN PERSONALIZED MEDICINE
8.2 INCREASING FOCUS ON DIGITAL BIOMARKERS
8.3 INCREASED DISCOVERY OF EPIGENETIC BIOMARKERS IN ONCOLOGY
9 MARKET GROWTH ENABLERS
9.1 INCREASE IN THE NUMBER OF PIPELINE BIOMARKERS
9.2 RISING ADOPTION OF BIOMARKERS IN DISEASE DIAGNOSTICS
9.3 TECHNOLOGICAL ADVANCEMENTS IN BIOMARKER DISCOVERY
10 MARKET RESTRAINTS
10.1 HIGH COST AND TIME-CONSUMING DEVELOPMENT
10.2 HIGH NUMBER OF FALSE DISCOVERIES
10.3 STRICT REGULATIONS AND ETHICS FOR BIOMARKER VALIDATION & QUALIFICATION
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY INDICATION
11.2.2 INSIGHTS BY APPLICATION
11.2.3 INSIGHTS BY TYPE
11.2.4 INSIGHTS BY GEOGRAPHY
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 INDICATION
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 ONCOLOGY
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 MARKET BY GEOGRAPHY
12.4 CARDIOLOGY
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 MARKET BY GEOGRAPHY
12.5 NEUROLOGY
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 MARKET BY GEOGRAPHY
12.6 IMMUNOLOGY
12.6.1 MARKET OVERVIEW
12.6.2 MARKET SIZE & FORECAST
12.6.3 MARKET BY GEOGRAPHY
12.7 OTHERS
12.7.1 MARKET OVERVIEW
12.7.2 MARKET SIZE & FORECAST
12.7.3 MARKET BY GEOGRAPHY
13 APPLICATION
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 DIAGNOSTICS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 DRUG DISCOVERY & DEVELOPMENT
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
13.5 PERSONALIZED MEDICINE
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MARKET BY GEOGRAPHY
13.6 OTHERS
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
13.6.3 MARKET BY GEOGRAPHY
14 TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 DIAGNOSTIC BIOMARKERS
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 MONITORING BIOMARKERS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 PROGNOSTIC BIOMARKERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 PREDICTIVE BIOMARKERS
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 SUSCEPTIBILITY BIOMARKERS
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
14.8 OTHER BIOMARKERS
14.8.1 MARKET OVERVIEW
14.8.2 MARKET SIZE & FORECAST
14.8.3 MARKET BY GEOGRAPHY
15 GEOGRAPHY
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 GEOGRAPHIC OVERVIEW
16 NORTH AMERICA
16.1 MARKET OVERVIEW
16.2 MARKET SIZE & FORECAST
16.3 NORTH AMERICA: TYPE
16.4 NORTH AMERICA: APPLICATION
16.5 NORTH AMERICA: INDICATION
16.6 KEY COUNTRIES
16.6.1 US: MARKET SIZE & FORECAST
16.6.2 CANADA: MARKET SIZE & FORECAST
17 EUROPE
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 EUROPE: TYPE
17.4 EUROPE: APPLICATION
17.5 EUROPE: INDICATION
17.6 KEY COUNTRIES
17.6.1 GERMANY: MARKET SIZE & FORECAST
17.6.2 FRANCE: MARKET SIZE & FORECAST
17.6.3 UK: MARKET SIZE & FORECAST
17.6.4 ITALY: MARKET SIZE & FORECAST
17.6.5 SPAIN: MARKET SIZE & FORECAST
18 APAC
18.1 MARKET OVERVIEW
18.2 APAC: TYPE
18.3 APAC: APPLICATION
18.4 APAC: INDICATION
18.5 KEY COUNTRIES
18.5.1 JAPAN: MARKET SIZE & FORECAST
18.5.2 CHINA: MARKET SIZE & FORECAST
18.5.3 INDIA: MARKET SIZE & FORECAST
18.5.4 SOUTH KOREA: MARKET SIZE & FORECAST
18.5.5 AUSTRALIA: MARKET SIZE & FORECAST
19 LATIN AMERICA
19.1 MARKET OVERVIEW
19.2 LATIN AMERICA: TYPE
19.3 LATIN AMERICA: APPLICATION
19.4 LATIN AMERICA: INDICATION
19.5 KEY COUNTRIES
19.5.1 BRAZIL: MARKET SIZE & FORECAST
19.5.2 MEXICO: MARKET SIZE & FORECAST
19.5.3 ARGENTINA: MARKET SIZE & FORECAST
20 MIDDLE EAST & AFRICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORRECAST
20.3 MIDDLE EAST & AFRICA: TYPE
20.4 MIDDLE EAST & AFRICA: APPLICATION
20.5 MIDDLE EAST & AFRICA: INDICATION
20.6 KEY COUNTRIES
20.6.1 TURKEY: MARKET SIZE & FORECAST
20.6.2 SOUTH AFRICA: MARKET SIZE & FORECAST
20.6.3 SAUDI ARABIA: MARKET SIZE & FORECAST
21 COMPETITIVE LANDSCAPE
21.1 COMPETITION OVERVIEW
21.2 MARKET SHARE ANALYSIS
21.2.1 ABBOTT
21.2.2 BIOMÉRIEUX
21.2.3 BIOHIT OYJ
21.2.4 CENTOGENE
21.2.5 CREATIVE DIAGNOSTICS
21.2.6 GE HEALTHCARE
21.2.7 ROCHE
21.2.8 TAMIRNA
21.2.9 FUJIREBIO
22 KEY COMPANY PROFILES
22.1 ABBOTT
22.1.1 BUSINESS OVERVIEW
22.1.2 MAJOR PRODUCT OFFERINGS
22.1.3 KEY STRATEGIES
22.1.4 KEY STRENGTHS
22.1.5 KEY OPPORTUNITIES
22.2 BIOMÉRIEUX
22.2.1 BUSINESS OVERVIEW
22.2.2 MAJOR PRODUCT OFFERINGS
22.2.3 KEY STRATEGIES
22.2.4 KEY STRENGTHS
22.2.5 KEY OPPORTUNITIES
22.3 BIOHIT OYJ
22.3.1 BUSINESS OVERVIEW
22.3.2 MAJOR PRODUCT OFFERINGS
22.3.3 KEY STRATEGIES
22.3.4 KEY STRENGTHS
22.3.5 KEY OPPORTUNITIES
22.4 CENTOGENE
22.4.1 BUSINESS OVERVIEW
22.4.2 MAJOR PRODUCT OFFERINGS
22.4.3 KEY STRATEGIES
22.4.4 KEY STRENGTHS
22.4.5 KEY OPPORTUNITIES
22.5 CREATIVE DIAGNOSTICS
22.5.1 BUSINESS OVERVIEW
22.5.2 MAJOR PRODUCT OFFERINGS
22.5.3 KEY STRATEGIES
22.5.4 KEY STRENGTHS
22.5.5 KEY OPPORTUNITIES
22.6 F. HOFFMANN-LA ROCHE
22.6.1 BUSINESS OVERVIEW
22.6.2 MAJOR PRODUCT OFFERINGS
22.6.3 KEY STRATEGIES
22.6.4 KEY STRENGTHS
22.6.5 KEY OPPORTUNITIES
22.7 FUJIREBIO
22.7.1 BUSINESS OVERVIEW
22.7.2 MAJOR PRODUCT OFFERINGS
22.7.3 KEY STRATEGIES
22.7.4 KEY STRENGTHS
22.7.5 KEY OPPORTUNITIES
22.8 GE HEALTHCARE
22.8.1 BUSINESS OVERVIEW
22.8.2 PRODUCT OFFERINGS
22.8.3 KEY STRATEGIES
22.8.4 KEY STRENGTHS
22.8.5 KEY OPPORTUNITIES
22.9 TAMIRNA
22.9.1 BUSINESS OVERVIEW
22.9.2 MAJOR PRODUCT OFFERINGS
22.9.3 KEY STRATEGIES
22.9.4 KEY STRENGTHS
22.9.5 KEY OPPORTUNITIES
23 OTHER PROMINENT VENDORS
23.1 ACCURE THERAPEUTICS
23.1.1 BUSINESS OVERVIEW
23.2 AGILENT
23.2.1 BUSINESS OVERVIEW
23.3 ALMAC GROUP
23.3.1 BUSINESS OVERVIEW
23.4 APPLIED RESEARCH USING OMIC SCIENCES (AROMICS)
23.4.1 BUSINESS OVERVIEW
23.5 BIO-RAD LABORATORIES
23.5.1 BUSINESS OVERVIEW
23.6 BIOVISION
23.6.1 BUSINESS OVERVIEW
23.7 CARIS LIFE SCIENCES
23.7.1 BUSINESS OVERVIEW
23.8 DENOVO BIOPHARMA
23.8.1 BUSINESS OVERVIEW
23.9 DREAMGENICS
23.9.1 BUSINESS OVERVIEW
23.10 EISAI
23.10.1 BUSINESS OVERVIEW
23.11 EPIGENOMICS
23.11.1 BUSINESS OVERVIEW
23.12 IMMUNOVIA
23.12.1 BUSINESS OVERVIEW
23.13 INSILICO MEDICINE
23.13.1 BUSINESS OVERVIEW
23.14 LEXOGEN
23.14.1 BUSINESS OVERVIEW
23.15 MONUMENT TX
23.15.1 BUSINESS OVERVIEW
23.16 ORYZON GENOMICS
23.16.1 BUSINESS OVERVIEW
23.17 PLEXISION
23.17.1 BUSINESS OVERVIEW
23.18 RULES-BASED MEDICINE
23.18.1 BUSINESS OVERVIEW
23.19 SIEMENS HEALTHINEERS
23.19.1 BUSINESS OVERVIEW
23.20 SECOND GENOME THERAPEUTICS
23.20.1 BUSINESS OVERVIEW
23.21 THERMO FISHER SCIENTIFIC
23.21.1 BUSINESS OVERVIEW
23.22 YMIR GENOMICS
23.22.1 BUSINESS OVERVIEW
24 REPORT SUMMARY
24.1 KEY TAKEAWAYS
24.2 STRATEGIC RECOMMENDATIONS
25 QUANTITATIVE SUMMARY
25.1 MARKET BY GEOGRAPHY
25.2 MARKET BY INDICATION
25.3 MARKET BY APPLICATION
25.4 MARKET BY TYPE
25.5 NORTH AMERICA MARKET BY INDICATION
25.6 NORTH AMERICA MARKET BY APPLICATION
25.7 NORTH AMERICA MARKET BY TYPE
25.8 EUROPE MARKET BY INDICATION
25.9 EUROPE MARKET BY APPLICATION
25.10 EUROPE MARKET BY TYPE
25.11 APAC MARKET BY INDICATION
25.12 APAC MARKET BY APPLICATION
25.13 APAC MARKET BY TYPE
25.14 LATIN AMERICA MARKET BY INDICATION
25.15 LATIN AMERICA MARKET BY APPLICATION
25.16 LATIN AMERICA MARKET BY TYPE
25.17 MIDDLE EAST & AFRICA MARKET BY INDICATION
25.18 MIDDLE EAST & AFRICA MARKET BY APPLICATION
25.19 MIDDLE EAST & AFRICA MARKET BY TYPE
26 APPENDIX
26.1 ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings